翰森制药集团有限公司（股票代码：03692）于2026年4月2日发布截至2026年3月31日止的股份变动月报表。公告显示，公司于本期未有新增发行、购回或注销股份，已发行股份数量维持6,055,150,070股不变，库藏股数为0股。
公司注册股本维持20,000,000,000股，面值为每股0.00001港元，总注册股本为200,000港元。截至报告期末，公司确认符合香港联交所规定的公众持股量要求。
此外，公司于2026年2月3日发行零息可换股债券（到期日为2033年），金额为4,680,000,000港元，转换价为每股57.39港元，若悉数行使最多可转换81,547,308股。报告期内未有就该可换股债券产生新增发行股份的情况。
公告由联席公司秘书钟胜利女士签署。公司表示，将继续严格遵守香港联交所《上市规则》及相关法律法规的要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.